| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
180,310,000 |
| Market
Cap: |
41.24(B) |
| Last
Volume: |
799,597 |
Avg
Vol: |
865,224 |
| 52
Week Range: |
$191.51 - $228.9 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Seagen is a biotechnology company that develops and commercializes targeted therapies to treat cancer. Co. is commercializing ADCETRIS®, or brentuximab vedotin, for the treatment of certain CD30-expressing lymphomas, PADCEV®, or enfortumab vedotin-ejfv, for the treatment of certain metastatic urothelial cancers, TIVDAK™, or tisotumab vedotin-tftv, for the treatment of certain metastatic cervical cancers, and TUKYSA®, or tucatinib, for treatment of certain metastatic HER2-positive breast cancers. Co. is also developing a pipeline of therapies for solid tumors and blood-related cancers designed to address unmet medical needs and improve treatment outcomes for patients.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
39,326 |
484,602 |
| Total Sell Value |
$0 |
$0 |
$8,245,949 |
$88,100,996 |
| Total People Sold |
0 |
0 |
7 |
8 |
| Total Sell Transactions |
0 |
0 |
18 |
70 |
| End Date |
2024-03-24 |
2023-12-22 |
2023-06-23 |
2022-06-23 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  14159, L.p. |
Director |
– • • |
2014-05-08 |
4/A |
B |
$33.72 |
$7,929,305 |
I/I |
233,055 |
369,522 |
2.25 |
- |
|
| 14159, L.p. |
Director |
– • • |
2014-05-07 |
4/A |
B |
$33.40 |
$3,938,140 |
I/I |
117,254 |
363,887 |
2.25 |
- |
|
| Siegall Clay B |
President and CEO |
• • – |
2014-04-03 |
4 |
AS |
$43.34 |
$242,702 |
D/D |
(5,600) |
955,696 |
|
- |
|
| Siegall Clay B |
President and CEO |
• • – |
2014-04-03 |
4 |
OE |
$5.92 |
$33,152 |
D/D |
5,600 |
961,296 |
|
- |
|
| Siegall Clay B |
President and CEO |
• • – |
2014-03-05 |
4 |
AS |
$52.89 |
$492,796 |
D/D |
(9,318) |
955,696 |
|
- |
|
| Siegall Clay B |
President and CEO |
• • – |
2014-03-05 |
4 |
OE |
$5.63 |
$54,084 |
D/D |
9,318 |
961,296 |
|
- |
|
| Boerner Christopher S. |
EVP, Commercial |
• – – |
2014-03-03 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
57,514 |
|
- |
|
| Himes Vaughn B |
EVP, Tech. Ops. & Proc. Sci. |
• – – |
2014-02-28 |
4 |
OE |
$9.23 |
$104,299 |
D/D |
11,300 |
55,519 |
|
- |
|
| Berger Franklin M |
Director |
– • – |
2014-02-21 |
4 |
OE |
$12.76 |
$95,700 |
D/D |
7,500 |
204,720 |
|
- |
|
| Boerner Christopher S. |
SVP, Commercial |
• – – |
2014-02-21 |
4 |
S |
$54.98 |
$79,825 |
D/D |
(1,452) |
46,075 |
|
- |
|
| Drachman Jonathan G |
CMO & EVP, R & D |
• – – |
2014-02-20 |
4 |
AS |
$53.25 |
$66,083 |
D/D |
(1,241) |
48,670 |
|
- |
|
| Himes Vaughn B |
EVP, Tech, Ops. & Proc. Sci. |
• – – |
2014-02-19 |
4 |
S |
$52.01 |
$264,627 |
D/D |
(5,088) |
44,219 |
|
- |
|
| Himes Vaughn B |
EVP, Tech, Ops. & Proc. Sci. |
• – – |
2014-02-19 |
4 |
OE |
$9.23 |
$27,690 |
D/D |
3,000 |
49,307 |
|
- |
|
| Siegall Clay B |
President and CEO |
• • – |
2014-02-18 |
4 |
S |
$51.97 |
$5,197,010 |
D/D |
(100,000) |
955,696 |
|
- |
|
| Siegall Clay B |
President and CEO |
• • – |
2014-02-13 |
4 |
OE |
$10.33 |
$125,427 |
D/D |
12,142 |
1,055,696 |
|
- |
|
| Dobmeier Eric |
Chief Operating Officer |
• – – |
2014-01-21 |
4 |
AS |
$47.87 |
$2,683,958 |
D/D |
(56,010) |
77,833 |
|
- |
|
| Drachman Jonathan G |
CMO & EVP, R & D |
• – – |
2014-01-16 |
4 |
AS |
$45.75 |
$54,946 |
D/D |
(1,201) |
49,911 |
|
- |
|
| Siegall Clay B |
President and CEO |
• • – |
2014-01-10 |
4 |
GD |
$0.00 |
$0 |
D/D |
5,000 |
1,038,554 |
|
- |
|
| Orwin John A |
Director |
– • – |
2014-01-10 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
5,000 |
|
- |
|
| Siegall Clay B |
President and CEO |
• • – |
2014-01-02 |
4 |
AS |
$39.27 |
$72,957 |
D/D |
(1,858) |
1,043,554 |
|
- |
|
| Siegall Clay B |
President and CEO |
• • – |
2014-01-02 |
4 |
OE |
$10.33 |
$19,193 |
D/D |
1,858 |
1,045,412 |
|
- |
|
| 14159, L.p. |
Director |
– • • |
2013-12-16 |
4 |
B |
$39.91 |
$3,143,952 |
I/I |
78,759 |
361,052 |
2.25 |
- |
|
| 14159, L.p. |
Director |
– • • |
2013-12-13 |
4 |
B |
$39.65 |
$1,733,276 |
I/I |
43,709 |
359,133 |
2.25 |
- |
|
| 14159, L.p. |
Director |
– • • |
2013-12-12 |
4 |
B |
$39.53 |
$11,268,200 |
I/I |
284,610 |
358,070 |
2.25 |
- |
|
| Siegall Clay B |
President and CEO |
• • – |
2013-12-05 |
4 |
OE |
$5.92 |
$112,456 |
D/D |
18,996 |
1,043,554 |
|
- |
|
1805 Records found
|
|
Page 39 of 73 |
|
|
